The option value of innovative treatments in the context of chronic myeloid leukemia.

The American journal of managed care

Volumn 18, Issue 11 Suppl, 2012, Pages

  Sanchez, Yuri ^a   Penrod, John R ^b   Qiu, Xiaoli Lily ^b   Romley, John ^b   Thornton Snider, Julia ^b   Philipson, Tomas ^b  

^a PRECISION HEALTH ECONOMICS   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN KINASE INHIBITOR;

BIOMEDICAL TECHNOLOGY ASSESSMENT; CANCER REGISTRY; HUMAN; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; SURVIVAL; UNITED STATES;

HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; PROTEIN KINASE INHIBITORS; SEER PROGRAM; SURVIVAL; TECHNOLOGY ASSESSMENT, BIOMEDICAL; UNITED STATES;

EID: 84891411331     PISSN: None     EISSN: 19362692     Source Type: Journal    
DOI: None     Document Type: Article

References (0)